Edgar Filing: KORMAN HARRY - Form 4

KORMAN H	ARRY									
Form 4 July 31, 2007										
								OMB A	PPROVAL	
FORM	4 UNITED	STATES		RITIES A Ashington			E COMMISSIO		3235-0287	
Check this			***	asinington	, D.C. 20	549		Expires:	January 31,	
if no longe subject to Section 16 Form 4 or	51AIEN 5.	MENT OI	F CHAI	NGES IN SECUI		ICIAL O	WNERSHIP OF	Estimated burden hou response	urs per	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type R	esponses)									
1. Name and Ac KORMAN H	ddress of Reporting	2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer					
	MYLAN LABORATORIES INC [MYL]				(Check all applicable)					
			Date of Earliest Transaction Ionth/Day/Year)			Director10% Owner Officer (give titleOther (specify				
				07/27/2007			below) below) Pres., Mylan Pharmaceuticals			
				If Amendment, Date Original			6. Individual or Joint/Group Filing(Check			
Filed(Month/Day/Year) Applicable Line) _X_Form filed by One Reporting Person										
(City)	(State)	(Zip)	Tal	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	2. Transaction Date Month/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	Disposed	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(D) Price	(
Reminder: Repo	ort on a separate line	e for each cl	ass of sec	urities bene	-	-	-			
					inforn requir	nation con red to resp ays a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securitie

Edgar Filing: KORMAN HARRY - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (or Disposed (D) (Instr. 3, 4, and 5)	d of	(Month/Day/Year)	(Instr. 3 and	4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Sha
Emp. Stock Option - Right to Buy	\$ 15.8	07/27/2007		A	80,000		07/27/2008(1)	07/27/2017	Common Stock	80,0
Restricted Stock Units	\$ 0	07/27/2007		А	8,000		<u>(2)</u>	<u>(2)</u>	Common Stock	8,00

Reporting Owners

Director10% OwnerOfficerOtherKORMAN HARRY 781 CHESTNUT RIDGE ROAD PO BOX 4310	Reporting Owner Name / Address	Relationships						
781 CHESTNUT RIDGE ROAD PO BOX 4310Pres., Mylan Pharmaceuticals		Director	10% Owner	Officer	Other			
MOKGANTOWN, WV 20303	781 CHESTNUT RIDGE ROAD			Pres., Mylan Pharmaceuticals				

Signatures

/s/Harry A. Korman 07/31/2007 <u>**Signature of Date</u> Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These options vest in four equal annual installments beginning on 07/27/2008.
- (2) Each restricted stock unit (RSU) represents the right to receive one share of Mylan Laboratories Inc. common stock. The RSUs vest in four equal annual installments beginning on 7/27/2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.